We are live on ! Find out more
EVH icon

Evolent Health

199 hedge funds and large institutions have $608M invested in Evolent Health in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more capital invested

Capital invested by funds: $253M → $608M (+$356M)

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

27% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 30

4% more funds holding

Funds holding: 192199 (+7)

6% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 64

0.61% more ownership

Funds ownership: 99.24%99.84% (+0.61%)

47% less call options, than puts

Call options by funds: $1.06M | Put options by funds: $2.01M

Holders
199
Holders Change
+7
Holders Change %
+3.65%
% of All Funds
2.4%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
38
Increased
68
Reduced
64
Closed
30
Calls
$1.06M
Puts
$2.01M
Net Calls
-$949K
Net Calls Change
-$886K

EVH Hedge Fund Activity: Q2 2026 in Review

199 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q2 2026, worth a combined $608M — up 141% from $253M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new EVH positions and 30 closed out — a net gain of 8 holders — while 68 added to existing stakes and 64 trimmed.

The largest buyer was BlackRock, adding an estimated $15.1M. The largest seller was UBS Group, cutting an estimated $7.3M.

  • 199 institutional investors held Evolent Health (EVH) as of Q2 2026, up from 192 in Q1 2026.
  • Funds reported $608M of Evolent Health stock for Q2 2026, up 141% quarter-over-quarter.
  • 38 funds opened new Evolent Health positions in Q2 2026 and 30 closed out, a net change of +8 holders.
  • The largest Evolent Health buyer in Q2 2026 was BlackRock, an estimated $15.1M added.
  • The largest Evolent Health seller in Q2 2026 was UBS Group, an estimated $7.3M sold.

Based on aggregated 13F filings for Q2 2026.